The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Because mutations, overexpression, and dysregulation of protein kinases play essential
roles in the pathogenesis of many illnesses, this enzyme family has become one of the most …

Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr)
protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein …

Cancer cells support their growth and proliferation by reprogramming their metabolism in
order to gain access to nutrients. Despite the heterogeneity in genetic mutations that lead to …

Renal cell carcinoma (RCC) is the most common and lethal tumor of the urological system.
Curative treatment of localized RCC includes nephrectomy, radio-ablation, and active …

The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of
feedback inhibition of receptor expression. To address these limitations, we designed a …

Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited
treatment options. The greatest advancement in treatments occurred in the 1980s when …

Papillary renal cell carcinoma: current and controversial is... : Current Opinion in Urology
Papillary renal cell carcinoma: current and controversial issues : Current Opinion in Urology …

Over-activation of the PI3K/Akt/mTOR network is a well-known pathogenic event that leads
to hyper-proliferation. Pharmacological targeting of this pathway has been developed for the …

Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular
endothelium growth factor (VEGF) plays a leading role in angiogenesis progression …